The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia

The soluble urokinase plasminogen activator receptor (suPAR) is a soluble form of the urokinase plasminogen activator receptor expressed in various immune and cancer cells. The levels of suPAR have been demonstrated to correlate with prognosis in various cancers. This study was intended to investiga...

Full description

Saved in:
Bibliographic Details
Published in:Turkish journal of haematology 2016-06, Vol.33 (2), p.135-140
Main Authors: Erkut, Nergiz, Menteşe, Ahmet, Özbaş, Hasan Mücahit, Ermantaş, Nilay, Sümer, Ayşegül, Örem, Asım, Sönmez, Mehmet
Format: Article
Language:English
Subjects:
acute myeloid leukemia
Adult
Aged
Aged, 80 and over
Biomarkers
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Female
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute - blood
Leukemia, Myeloid, Acute - diagnosis
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - mortality
Male
Middle Aged
Prognosis
Receptors, Urokinase Plasminogen Activator - blood
ROC Curve
soluble urokinase plasminogen activator receptor
Young Adult
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The soluble urokinase plasminogen activator receptor (suPAR) is a soluble form of the urokinase plasminogen activator receptor expressed in various immune and cancer cells. The levels of suPAR have been demonstrated to correlate with prognosis in various cancers. This study was intended to investigate serum suPAR levels and their effect on prognosis in patients with acute myeloid leukemia (AML). Thirty newly diagnosed patients with AML and 29 healthy individuals were enrolled. Serum suPAR levels were analyzed by enzyme-linked immunosorbent assay. Serum suPAR levels were significantly higher in patients with AML than in healthy individuals (9±5.9 ng/mL and 2.4±1.4 ng/mL, respectively; p
ISSN:1300-7777
1308-5263
DOI:10.4274/tjh.2014.0405